Laura Peter emphasized the broader implications of the Bayh-Dole Act, stating, "Bayh-Dole applies much more broadly than drug pricing and life sciences. I hope it continues to be as strong and supported as it has been in the past." This reflects the sentiment that its stability is critical for ongoing university innovation and technology transfers.
Panelists expressed concerns regarding the proposed march-in framework, with Becky Kaufman noting, "If the march-in rights are expanded as proposed, it would represent a significant setback for our technology transfer efforts, potentially stifling innovation and collaboration with industry partners in academia." This highlights the potential negative impact on university-industry partnerships.
Patricia Stepp articulated the practical concerns of the proposal, stating, "The implementation of these changes could force us to rethink how we approach commercialization altogether, possibly leading to a chilling effect on our licensing processes and relationships with potential commercial partners." Her insights shed light on the hurdles in adapting to new guidelines.
[
Collection
]
[
|
...
]